GSK to pull blood cancer drug from US market after study failure

Photo caption: A GSK building in London. Photo courtesy of GSK. Article by Ned Pagliarulo. BioPharma Dive – November 22, 2022.

GSK will pull a blood cancer drug from the U.S. market after the treatment failed in a confirmatory clinical trial, the British drugmaker announced Tuesday. Following a request from the Food and Drug Administration, GSK has begun the process of withdrawing its approved multiple myeloma therapy Blenrep. […]

Click here to view original web page at www.biopharmadive.com